The company
aTyr Pharma, Inc.
ATYR · Nasdaq
ATYR stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 69.3% below that average now. Biotechnology: 17% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 27% (−6 points in four weeks).
Statistics
- Last close, 22 Oct 2026
- 0.17 −1.33%
- 52-week range
- —
- Volume
- 1.04M
- Average volume (50 days)
- —
- Relative volume
- —
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 52
- Industry in uptrend
- 17% -9 in 4 wk
- Insider buys, 12 months
- $100K
- Insider sales, 12 months
- $13K
- Officials’ trades on record
- 0
- Institutions holding
- 86 (-19)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Price and volume
Daily bars to 22 Oct 2026: 29 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Paul SchimmelDirector | bought | 100,000at $0.4963 | 27 May 2026filed 28 May 2026 |
| Nancy DenyesGeneral Counsel | sold | 1,118at $0.9761 | 4 Feb 2026filed 4 Feb 2026 |
| Jill Marie BroadfootChief Financial Officer | sold | 1,558at $0.976 | 4 Feb 2026filed 4 Feb 2026 |
| Sanjay ShuklaPresident and CEO | sold | 3,745at $0.976 | 4 Feb 2026filed 4 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FEDERATED HERMES, INC.reduced · filed 12 Aug 2026 | 8,509,678$5.1M | -2,000,000−19.0% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 3,808,091$2.3M | -4,041−0.1% |
| AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026 | 2,610,548$1.6M | +2,114,530+426.3% |
| FMR LLCreduced · filed 13 Aug 2026 | 2,471,418$1.5M | -12,235,425−83.2% |
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 1,827,332$1.1M | -4,616,572−71.6% |
| Kalehua Capital Management LLCnew · filed 14 Aug 2026 | 1,788,167$1.1M | +1,788,167 |
| JANE STREET GROUP, LLCadded · filed 14 Aug 2026 | 1,721,297$1.0M | +1,672,795+3448.9% |
| UBS Group AGreduced · filed 13 Aug 2026 | 1,531,151$914K | -2,336,062−60.4% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 1,343,636$802K | +118,169+9.6% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 1,245,147$743K | +100,582+8.8% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.